EDIT Insider Trading
Insider Ownership Percentage: 1.90%
Insider Buying (Last 12 Months): $253,800.00
Insider Selling (Last 12 Months): $180,348.49
Editas Medicine Insider Trading History Chart
This chart shows the insider buying and selling history at Editas Medicine by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Editas Medicine Share Price & Price History
Current Price: $1.15
Price Change: ▼ Price Decrease of -0.015 (-1.29%)
As of 04/1/2025 04:40 PM ET
Editas Medicine Insider Trading History
Editas Medicine Institutional Trading History
Data available starting January 2016
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Read More on Editas Medicine
Volume
1,610,132 shs
Average Volume
2,542,744 shs
Market Capitalization
$95.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.88
Who are the company insiders with the largest holdings of Editas Medicine?